Edwards Lifesciences — Oct 30, 2025 release

Recent Highlights • Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted 1 , with strength across all product groups • Q3 TAVR sales grew 12.4%; constant currency 1 sales grew 10.6% • Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE • Q3 EPS of $0.50 2 ; adjusted 1 EPS of $0.67 • SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling long-term outcomes equivalent to surgery at 7 years, further supported by 10-year follow-up of PARTNER 2 studies • New ESC/EACTS guidelines simplify care pathways for all severe AS patients • EVOQUE real-world data from over 1,000 patients showed impressive safety and efficacy results • SAPIEN M3 achieved primary endpoint in pivotal ENCIRCLE trial for mitral replacement 2025 Full-Year Outlook • Increasing sales growth guidance to high end of 9-10% from 9-10% • Increasing TAVR sales guidance to 7-8% from 6-7% • Increasing adjusted 1 EPS guidance to $2.56 to $2.62 from the high end of $2.45 to $2.55 “Our strong results represent another quarter of double-digit sales growth, driven by our comprehensive portfolio across multiple therapeutic areas – aortic, pulmonic, mitral and tricuspid – and our established presence in countries around the world,” said Bernard Zovighian, CEO. “Based on our better-than-expected performance, reflecting the patient-focused contributions of our talented employees, we are raising our 2025 sales and EPS guidance. Edwards remains committed to being the partner of choice for heart teams by providing a complete portfolio of therapies for the many patients in need, built on the foundation of our unique strategy and an unprecedented body of evidence. Our focus on structural heart, including extending into heart failure and aortic regurgitation, represents a tremendous opportunity with the potential to drive differentiated long-term value.” Transcatheter Aortic Valve Replacement (TAVR) In the third quarter, Edwards’ TAVR sales of $1.15 billion grew 12.4% vers us the prior year or 10.6% on a constant currency basis. Constant currency growth was comparable in the United States and outside of the U.S. On a global basis, Ed